Perrigo to sell Dermacosmetics business to KKR for up to €327M

PERRIGO Co plc

Upfront cash €300M, plus up to €27M milestone payments over three years.
Divestiture includes brands ACO, Biodermal, Emolium, Iwostin; 2024 net sales ~€125M.
Expected to close Q1 2026; net proceeds to strengthen balance sheet.
Advances Perrigo's 'Three-S' plan to streamline portfolio and focus on high-growth brands.
Business generated ~5% of Perrigo's 2024 adjusted operating income.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.